Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial

Susan G. Hilsenbeck, C. Kent Osborne, Myles Brown, James Ingle, Steven Come, Rakesh Kumar, Mitch Dowsett, Aman Buzdar, Eric Winer

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: Subset analysis from the Arimidex, Tamoxifen, Alone or in Combination trial, a major adjuvant therapy trial, suggests that progesterone receptor - negative (PR-) cases may derive greater benefit from aromatase inhibitor compared with tamoxifen than PR+ cases. We postulated that estrogen receptor-positive (ER+)/PR+ patients might do as well or better by starting on tamoxifen and later switching to an aromatase inhibitor rather than by starting on an aromatase inhibitor as initial therapy. Experimental Design: We constructed a computer model using retrospective data to approximate exponential failure rates for PR+ and PR- in tamoxifen-treated and tamoxifen-untreated patients, adding the assumptions that about half of patients are cured at surgery and that ∼ 20% of postmenopausal ER+ early breast cancer cases are PR-. This model provided a very good approximation to the published overview data and to the clinical trials. We then used the failure rates to generate relapse times for a large number of cases (n = 50,000) for each treatment scenario. Results: In PR- cases, initial therapy with an aromatase inhibitor is superior to tamoxifen and this advantage can never be made up by switching. In PR+ cases, tamoxifen is only modestly inferior to aromatase inhibitor at the outset, and after switching to an aromatase inhibitor at 3 or 5 years the tamoxifen relapse-free survival curve catches up and then begins to surpass the aromatase inhibitor curve at 7.5 or 12 years, respectively. Discussion: Although our in silico trial is based on many assumptions, it closely approximates results of the published trials and, therefore, suggests that an in vivo comparison in ER+/PR+ patients of aromatase inhibitor versus tamoxifen followed by aromatase inhibitor may be worth considering.

Original languageEnglish (US)
JournalClinical Cancer Research
Volume12
Issue number3 II
DOIs
StatePublished - Feb 1 2006
Externally publishedYes

Fingerprint

Aromatase Inhibitors
Progesterone Receptors
Tamoxifen
Computer Simulation
Clinical Trials
Breast Neoplasms
Recurrence
Therapeutics
Estrogen Receptors
Research Design
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. / Hilsenbeck, Susan G.; Osborne, C. Kent; Brown, Myles; Ingle, James; Come, Steven; Kumar, Rakesh; Dowsett, Mitch; Buzdar, Aman; Winer, Eric.

In: Clinical Cancer Research, Vol. 12, No. 3 II, 01.02.2006.

Research output: Contribution to journalArticle

Hilsenbeck, SG, Osborne, CK, Brown, M, Ingle, J, Come, S, Kumar, R, Dowsett, M, Buzdar, A & Winer, E 2006, 'Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial', Clinical Cancer Research, vol. 12, no. 3 II. https://doi.org/10.1158/1078-0432.CCR-05-2123
Hilsenbeck, Susan G. ; Osborne, C. Kent ; Brown, Myles ; Ingle, James ; Come, Steven ; Kumar, Rakesh ; Dowsett, Mitch ; Buzdar, Aman ; Winer, Eric. / Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 3 II.
@article{cef861540f7e439281ded62a118276c5,
title = "Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial",
abstract = "Purpose: Subset analysis from the Arimidex, Tamoxifen, Alone or in Combination trial, a major adjuvant therapy trial, suggests that progesterone receptor - negative (PR-) cases may derive greater benefit from aromatase inhibitor compared with tamoxifen than PR+ cases. We postulated that estrogen receptor-positive (ER+)/PR+ patients might do as well or better by starting on tamoxifen and later switching to an aromatase inhibitor rather than by starting on an aromatase inhibitor as initial therapy. Experimental Design: We constructed a computer model using retrospective data to approximate exponential failure rates for PR+ and PR- in tamoxifen-treated and tamoxifen-untreated patients, adding the assumptions that about half of patients are cured at surgery and that ∼ 20{\%} of postmenopausal ER+ early breast cancer cases are PR-. This model provided a very good approximation to the published overview data and to the clinical trials. We then used the failure rates to generate relapse times for a large number of cases (n = 50,000) for each treatment scenario. Results: In PR- cases, initial therapy with an aromatase inhibitor is superior to tamoxifen and this advantage can never be made up by switching. In PR+ cases, tamoxifen is only modestly inferior to aromatase inhibitor at the outset, and after switching to an aromatase inhibitor at 3 or 5 years the tamoxifen relapse-free survival curve catches up and then begins to surpass the aromatase inhibitor curve at 7.5 or 12 years, respectively. Discussion: Although our in silico trial is based on many assumptions, it closely approximates results of the published trials and, therefore, suggests that an in vivo comparison in ER+/PR+ patients of aromatase inhibitor versus tamoxifen followed by aromatase inhibitor may be worth considering.",
author = "Hilsenbeck, {Susan G.} and Osborne, {C. Kent} and Myles Brown and James Ingle and Steven Come and Rakesh Kumar and Mitch Dowsett and Aman Buzdar and Eric Winer",
year = "2006",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-05-2123",
language = "English (US)",
volume = "12",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3 II",

}

TY - JOUR

T1 - Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial

AU - Hilsenbeck, Susan G.

AU - Osborne, C. Kent

AU - Brown, Myles

AU - Ingle, James

AU - Come, Steven

AU - Kumar, Rakesh

AU - Dowsett, Mitch

AU - Buzdar, Aman

AU - Winer, Eric

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Purpose: Subset analysis from the Arimidex, Tamoxifen, Alone or in Combination trial, a major adjuvant therapy trial, suggests that progesterone receptor - negative (PR-) cases may derive greater benefit from aromatase inhibitor compared with tamoxifen than PR+ cases. We postulated that estrogen receptor-positive (ER+)/PR+ patients might do as well or better by starting on tamoxifen and later switching to an aromatase inhibitor rather than by starting on an aromatase inhibitor as initial therapy. Experimental Design: We constructed a computer model using retrospective data to approximate exponential failure rates for PR+ and PR- in tamoxifen-treated and tamoxifen-untreated patients, adding the assumptions that about half of patients are cured at surgery and that ∼ 20% of postmenopausal ER+ early breast cancer cases are PR-. This model provided a very good approximation to the published overview data and to the clinical trials. We then used the failure rates to generate relapse times for a large number of cases (n = 50,000) for each treatment scenario. Results: In PR- cases, initial therapy with an aromatase inhibitor is superior to tamoxifen and this advantage can never be made up by switching. In PR+ cases, tamoxifen is only modestly inferior to aromatase inhibitor at the outset, and after switching to an aromatase inhibitor at 3 or 5 years the tamoxifen relapse-free survival curve catches up and then begins to surpass the aromatase inhibitor curve at 7.5 or 12 years, respectively. Discussion: Although our in silico trial is based on many assumptions, it closely approximates results of the published trials and, therefore, suggests that an in vivo comparison in ER+/PR+ patients of aromatase inhibitor versus tamoxifen followed by aromatase inhibitor may be worth considering.

AB - Purpose: Subset analysis from the Arimidex, Tamoxifen, Alone or in Combination trial, a major adjuvant therapy trial, suggests that progesterone receptor - negative (PR-) cases may derive greater benefit from aromatase inhibitor compared with tamoxifen than PR+ cases. We postulated that estrogen receptor-positive (ER+)/PR+ patients might do as well or better by starting on tamoxifen and later switching to an aromatase inhibitor rather than by starting on an aromatase inhibitor as initial therapy. Experimental Design: We constructed a computer model using retrospective data to approximate exponential failure rates for PR+ and PR- in tamoxifen-treated and tamoxifen-untreated patients, adding the assumptions that about half of patients are cured at surgery and that ∼ 20% of postmenopausal ER+ early breast cancer cases are PR-. This model provided a very good approximation to the published overview data and to the clinical trials. We then used the failure rates to generate relapse times for a large number of cases (n = 50,000) for each treatment scenario. Results: In PR- cases, initial therapy with an aromatase inhibitor is superior to tamoxifen and this advantage can never be made up by switching. In PR+ cases, tamoxifen is only modestly inferior to aromatase inhibitor at the outset, and after switching to an aromatase inhibitor at 3 or 5 years the tamoxifen relapse-free survival curve catches up and then begins to surpass the aromatase inhibitor curve at 7.5 or 12 years, respectively. Discussion: Although our in silico trial is based on many assumptions, it closely approximates results of the published trials and, therefore, suggests that an in vivo comparison in ER+/PR+ patients of aromatase inhibitor versus tamoxifen followed by aromatase inhibitor may be worth considering.

UR - http://www.scopus.com/inward/record.url?scp=32944467692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944467692&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-2123

DO - 10.1158/1078-0432.CCR-05-2123

M3 - Article

C2 - 16467123

AN - SCOPUS:32944467692

VL - 12

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3 II

ER -